ArticleCurrent fungal infection reports2014
Epidemiology of echinocandin resistance in
Article in Current fungal infection reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- From Species Identification to Empirical Therapy: A Machine Learning and Rule-Based Decision Support Framework for Antifungal Resistance Prediction in ICUMedical sciences (Basel, Switzerland) · 2026Article
- Article
- Echinocandin Adaptation inJournal of fungi (Basel, Switzerland) · 2025Article
- Post-transcriptional control of antifungal resistance in human fungal pathogens.Critical reviews in microbiology · 2023Review
- Evaluation of an Antifungal Stewardship Initiative Targeting Micafungin at an Academic Medical Center.Antibiotics (Basel, Switzerland) · 2023Article
- Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.The Journal of antimicrobial chemotherapy · 2022Review
- Danish Whole-Genome-SequencedJournal of fungi (Basel, Switzerland) · 2021Article
- Phytomedicine from Middle Eastern Countries: An Alternative Remedy to Modern Medicine againstEvidence-based complementary and alternative medicine : eCAM · 2021Review
- Mechanisms of action of antimicrobial peptides ToAP2 and NDBP-5.7 against Candida albicans planktonic and biofilm cells.Scientific reports · 2020Article
- Review on Current Status of Echinocandins Use.Antibiotics (Basel, Switzerland) · 2020Review
- Review
- Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Echinocandins are the newest antifungal agents approved for use in treating
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.